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Abstract
Rheumatoid arthritis (RA) is a complex polygenic inflammatory disease associated with accelerated atherosclerosis
and increased risk of cardiovascular (CV) disease. Previous genome-wide association studies have described
SMAD3 rs17228212 polymorphism as an important signal associated with CV events. The aim of the present study
was to evaluate for the first time the relationship between this gene polymorphism and the susceptibility to CV
manifestations and its potential association with the presence of subclinical atherosclerosis assessed by the
evaluation of carotid intima-media thickness (cIMT) in patients with RA.
Methods: One thousand eight hundred and ninety-seven patients fulfilling classification criteria for RA were
genotyped for SMAD3 rs17228212 gene polymorphism through TaqMan genotyping assay. Also, subclinical
atherosclerosis determined by the assessment of cIMT was analyzed in a subgroup of these patients by carotid
ultrasonography.
Results: No statistically significant differences were observed when allele frequencies of RA patients with or without
CV events were compared. Nevertheless, when RA patients were stratified according to anti-cyclic citrullinated
peptide (anti-CCP) status, we found that in RA patients who were negative for anti-CCP antibodies, the presence of
C allele of SMAD3 rs17228212 polymorphism conferred a protective effect against the risk of cerebrovascular
accident (CVA) after adjustment for demographic and classic CV risk factors (HR [95%CI]=0.36 [0.14–0.94],
p=0.038) in a Cox regression model. Additionally, correlation between the presence of C allele of SMAD3
rs17228212 polymorphism and lower values of cIMT was found after adjustment for demographic and classic CV risk
factors (p-value=0.0094) in the anti-CCP negative RA patients.
Conclusions: Our results revealed that SMAD3 rs17228212 gene variant is associated with lower risk of CVA and
less severe subclinical atherosclerosis in RA patients negative for anti-CCP antibodies. These findings may have
importance to establish predictive models of CV disease in RA patients according to anti-CCP status.
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Introduction
Rheumatoid arthritis (RA) is a complex autoimmune disease
associated with progressive disability, systemic complications
and early death. Mortality is higher among RA patients than in
the general population, and cardiovascular (CV) complications
remain a major challenge [1]. Atherosclerosis is the main cause
of increased CV morbidity and mortality in RA patients. As well
as traditional CV risk factors, chronic systemic inflammation
plays a pivotal role in the development of accelerated
atherosclerosis observed in RA [2]. Moreover, recent studies
have also highlighted the implication of genetic factors in the
susceptibility to and/or risk of accelerated atherosclerosis of
patients with RA [3-5].
Genome-wide Association studies of coronary artery disease
(CAD) performed in Caucasian populations have identified a
number of genetic variants that were associated with this
pathology. In this regard, variant rs17228212 of SMAD3
located in 15q22.33 chromosomal region was detected after a
combined meta-analysis between the Wellcome Trust Case
Control Consortium study and The German Myocardial
Infarction Family Study, with high probability of a true
association [6]. SMAD3 gene encodes an intracellular signal
transducer and transcriptional modulator activated by
transforming growth factor-beta (TGF-β) and activin type 1
receptor kinases. Smad3 is directly phosphorylated by the
activated type I receptors on its C-terminal Ser-Ser-X-Ser motif.
This C-terminal phosphorylation allows binding to common
mediator Smads and translocation to the nucleus where they
can recruit transcriptional co-activators or co-repressors and
regulate TGF-β target genes [7]. In the immune system, TGF-β
modulates the balance of proinflammatory and anti-
inflammatory T-cells through a complex set of interactions.
SMAD3 has an essential role in downregulating T-cells and
increasing expression of FoxP3, an essential step in the
differentiation of regulatory T-cells [8]. Imbalance of
proinflammatory Th17 and regulatory T-cells has been reported
in acute coronary syndrome [9].
Besides, a SMAD3 haplotype has been associated with
Kawasaki disease, a systemic vasculitis disease associated
with cardiovascular sequelae [10]. Moreover, gene variants in
SMAD3 have been associated with inflammatory bowel
disease and asthma [11].
Taking into account all these considerations, in the present
study we aimed to assess, for the first time, the potential
implication of the SMAD3 rs17228212 polymorphism in the
susceptibility to CV manifestations and its possible association
with the presence of subclinical atherosclerosis assessed by
the evaluation of carotid intima-media thickness (cIMT) using
carotid ultrasonography (US) in RA in a large and well
characterized cohort of Spanish RA patients.
Materials and Methods
Patients and Study Protocol
Ethics Statement.  A subject’s written consent was obtained
according to the declaration of Helsinki, and purpose of the
work was approved by the Ethics Committee of Galicia (Spain).
The Ethics Committees of the Hospital Universitario Marqués
de Valdecilla (Santander), Hospital Universitario Bellvitge
(Barcelona), Hospital Universitario La Paz, Hospital de La
Princesa, Hospital Clínico San Carlos, Hospital 12 de Octubre
and Hospital Universitario Gregorio Marañón (Madrid) also
approved the study.
A cohort of 1897 RA Spanish patients were included in the
present study. Blood samples were obtained from patients
recruited from diverse Spanish Hospitals mentioned above. All
the patients fulfilled the 1987 American College of
Rheumatology (ACR) criteria for the classification of RA [12]
and also the 2010 classification criteria for RA [13]. Between
December 2009 and January 2013 patient’s clinical records
were examined until patient’s death, loss of follow-up or
December 1st, 2012.
Information on the main demographical data, clinical
characteristics of the patients enrolled in the study and risk
factors of patients are shown in Table 1. Three hundred and
sixty-nine (19.45%) of these 1897 RA patients had experienced
clinically evident CV events: a CV event was considered to be
present if the patient had ischemic heart disease (IHD)
(9.76%), cerebrovascular accidents (CVA) (5.43%), heart
failure (HF) (6.07%) or peripheral arteriopathy (2.53%). Clinical
definitions for CV events and classic CV risk factors were
described elsewhere [14,15]. Briefly, definition of IHD included
acute coronary syndromes with or without persistent ST-
segment elevation and chronic coronary heart disease. Data
regarding the clinical presentation of HF were collected for all
patients, based on the Framingham criteria [16]. A patient was
considered to have a CVA when he/she had a stroke and/or
transient ischemic attacks (TIAs). Strokes were classified
according to their clinical features and they were confirmed by
computed tomography and/or magnetic resonance imaging.
TIAs were diagnosed if the symptoms were self-limited in less
than 24 hours, without residual neurological damage.
Peripheral arterial disease was considered present if it was
confirmed by Doppler and/or arteriography [15]. Information on
the clinical characteristics and risk factors of RA patients who
suffered CVA are shown in Table S1 in File S1.
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Genotyping
DNA from patients was obtained from peripheral blood using
standard methods. DNA patient was assessed for rs17228212
SMAD3 polymorphism through TaqMan single nucleotide
polymorphism (SNP) genotyping assay (C__33991364_10) in a
7900 HT real-time Polymerase Chain Reaction system,
according to the manufacturer´ recommended conditions
(Applied Biosystems, Foster City, CA, USA). Negative controls
and duplicate samples were included to check genotyping
accuracy.
Carotid ultrasonography (US) examination
Measurement of the cIMT was performed in 444 patients
from Lugo and Santander by carotid US. Patients from
Santander were assessed using a commercially available
scanner, Mylab 70, Esaote (Genoa, Italy) equipped with 7–12
MHz linear transducer and the automated software guided
technique radiofrequency—Quality Intima Media Thickness in
real-time (QIMT, Esaote, Maastricht, Holland)—was used [17].
Patients from Lugo were evaluated using high-resolution B-
mode ultrasound, Hewlett Packard SONOS 5500, with a 10-
MHz linear transducer as previously reported [18]. cIMT was
Table 1. Demographic characteristics of the RA patients
included in the study.
Clinical Feature % (n/N)
Absence of
CV events, %
(n)
Presence of
CV events, %
(n) p
Main Characteristics     
Women 74.06(1405/1897) 77.62 (1186) 59.35 (219) <10
-7
Age of patients at the
time of disease
diagnosis, years,
median (IQR)
54 (43-64) 52 (42-62) 62 (53-70) <10-3
Time follow-up, years,
median (IQR) 9.9 (5-16.5) 9 (4-15) 12 (6-19) 0.01
anti-CCP positive 58.71 (927/1579) 59.40 (774) 55.43 (153) N.S.
Rheumatoid Factor
positive
66.78
(1194/1788) 67.19 (981) 64.94 (213) N.S.
Erosions 54.93 (763/1389) 55.08 (629) 54.25 (134) N.S.
Extra-articular
Manifestations 32.05 (449/1401) 31.11 (354) 36.12 (95) N.S.
Cardiovascular Risk
Factors     
Hypertension 38.49 (722/1876) 33.16 (503) 61.00 (219) <10-7
Diabetes mellitus 12.72 (238/1871) 10.18 (154) 23.46 (84) <10-7
Dyslipidemia 36.33 (675/1858) 33.27 (500) 49.30 (175) <10-7
Obesity 20.26 (343/1693) 19.31 (268) 24.59 (75) 0.038
Smoking habit* 33.33 (619/1821) 31.85 (467) 42.82 (152) <10-4
Except where indicated otherwise, values are % (n/N).
CV: Cardiovascular. IQR: Interquartile Range. Anti-CCP: anti-cyclic citrullinated
peptide antibodies. N.S.: Non significant.Smoking habit*: including active smoker
patients´ and patients who had ever smoked.
doi: 10.1371/journal.pone.0077695.t001
measured at the far wall of the right and left common carotid
arteries, 10 mm from the carotid bifurcation, over the proximal
15 mm-long segment. cIMT was determined as the average of
three measurements in each common carotid artery. The final
cIMT was the largest average cIMT (left or right). Agreement
between the two US methods in patients with RA was high [19].
Two experts with high experience and close collaboration in the
assessment of cIMT in RA from Santander (AC) and Lugo
(CGJ) performed the studies.
Statistical analysis
All genotype data were checked for deviation from Hardy-
Weinberg equilibrium (HWE) using http://ihg.gsf.de/cgi-bin/hw/
hwa1.pl. Both allelic and genotypic frequencies were calculated
and compared by χ2 or Fisher tests using the StatsDirect
software V2.6.6 (StatsDirect http://www.statsdirect.com,
England: StatsDirect 2008). Strength of associations between
CV events and alleles were estimated using Odds Ratios (OR)
and 95% Confidence Intervals (CI), via multiple logistic
regression; estimates were further adjusted for sex, age at RA
diagnosis, time of follow-up and classic CV risk factors
(hypertension, diabetes mellitus, dyslipidemia, obesity, and
smoking habit).
The relationship between SMAD3 rs17228212 genotypes
and CV events which appeared in the follow-up was tested
using Cox proportional hazards model, adjusting for sex, age at
RA diagnosis and traditional CV risk factors (hypertension,
diabetes mellitus, dyslipidemia, obesity, and smoking habit).
For that purpose, we used CC genotype as reference; the end
of follow-up was the first date among the end of the study
(December-2012), date of death, or date of CV event. Follow-
up time was estimated as the difference between the RA
diagnosis date and the end of follow-up. Patients without CV
event in the follow-up time or dying by any other causes
different from CV events were considered as censored. Results
are expressed as Hazard Ratios (HR) with 95% Confidence
Interval (CI). Survival curves were constructed using the
Kaplan–Meier method.
The association between genotypes of the SMAD3
rs17228212 gene variant and cIMT was tested using unpaired
T-test to compare between 2 groups, and one-way analysis of
variance (ANOVA) to compare among more than two groups.
Moreover, we also assessed the association between cIMT
and alleles using analysis of covariance (ANCOVA) adjusting
for sex, age and duration of the disease at the time of the
carotid US study and traditional CV risk factors.
Statistical significance was defined as p<0.05. All analyses
were performed with STATA statistical software 12/SE. (Stata
Corp., College Station, TX, USA).
Results
Genotyping success rate in our study was higher than
96.5%. No deviation from Hardy-Weinberg equilibrium (HWE)
was detected (p=0.23).
As shown in Table 1, patients with CV events were older at
the time of disease diagnosis, were more likely to be men, and
more often had hypertension, diabetes mellitus, dyslipidemia
SMAD3 and Cerebrovascular Accidents in RA
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and obesity. In addition, smoking habit (defined as those
patients who smoked at the time of disease diagnosis, during
the follow-up or who had smoked within 10 years before the
onset of RA symptoms or disease diagnosis) was more
frequent in men than in women RA patients (58.88% vs.
25.99%).
No differences were observed when allele frequencies from
patients with or without CV events were compared (MAF: 0.269
and 0.262, respectively; p=0.70). Results from an adjusted
logistic regression model did not show statistically significant
association: OR (95%CI)=0.88 (0.68-1.13), p=0.31. Neither a
statistically significant result was obtained applying a Cox
regression model to estimate the influence of the SMAD3
rs17228212 genetic variant on risk of CV disease, which was
adjusted for sex, age at the time of RA diagnosis, and
traditional CV risk factors as potential confounders: HR
[95%CI]=0.93 [0.74-1.18], p=0.56. Neither association was
detected for the risk of developing IHD (p=0.21), CVA (p=0.30),
HF (p=0.27), or peripheral vascular events (p=0.27) in the
whole RA patient´ cohort.
Nevertheless, when the cohort of RA patients was stratified
according to presence or absence of anti-cyclic citrullinated
peptide (anti-CCP) antibodies, differences in the risk of CV
events in general (as a whole) or in the risk of suffering any of
the different subtypes of CV events (IHD, CVA or HF) in
patients who were negative for these antibodies were observed
(Table 2). In a further step, we performed a Cox regression
model to account for the variation of risk of the first CV event
through time according to allele C of rs17228212 SMAD3
variant: in the subgroup of anti-CCP negative RA patients the
presence of C allele conferred a protective effect against CVA
after result adjustment for sex, age at the time of RA diagnosis,
and traditional CV risk factors (HR [95%CI]=0.36 [0.14–0.94],
p=0.038), while C allele carriers who were positive for anti-CCP
antibodies did not show any reduction in the risk of CVA (HR
[95%CI]=1.08 [0.55–2.10], p=0.82) (Table 3). Similar results
were found when Kaplan-Meier survival curves were
constructed (Suppl. Figures A-F in File S1). No other
significant results were obtained in the Cox model for any of
the other CV events subtypes (data not shown).
Finally, as shown in Table 2, the risk of IHD or HF was
increased in RA patients carrying the C allele. Although results
did not reach statistical significance, this increase of C allele
frequency is in line with previous results that reported an
increased risk of CAD associated to C allele in individuals
without RA [6].
Furthermore, analysis of the cIMT in anti-CCP negative
patients showed slight differences in this parameter as
exposed in Table 4. Regarding this, when association between
SMAD3 rs17228212 polymorphism and cIMT values was
adjusted for potential confounders in the ANCOVA model,
results disclosed that the presence of the C allele in the
subgroup of anti-CCP negative RA patients was associated
with significantly lower cIMT values than those found in anti-
CCP negative patients carrying the T allele (p-value=0.0094).
In our model, we took into account traditional CV Framingham
risk factors criteria as confounder factors. Nevertheless if we
had only adjusted our model by smoking habit and
hypertension and not for other traditional CV risk factors, as
other authors have been recently published [20], the results still
would been statistically significant for the cIMT ANCOVA
model: p=0.014.
In RA patients positive for anti-CCP antibodies, results for
cIMT in the ANCOVA model were not statistically significant
(Table 4).
Discussion
Our results indicate a potential association of the SMAD3
rs17228212 gene variant with CVA and subclinical
atherosclerosis in RA patients who are negative for anti-CCP
antibodies. CVA is one of the leading causes of death and
disability worldwide. cIMT is a good surrogate marker of
Table 3. Cox regression model to account for the risk of
cerebrovascular accident (CVA).
 CVA
CVA in anti-CCP
positive patients
CVA in anti-CCP
negative patients
HR [95%CI];
p
0.78 [0.49-1.24];
p=0.30
1.08 [0.55–2.10];
p=0.82
0.36 [0.14–0.94];
p=0.038
HR [95%CI]: Hazard Ratios with 95% Confidence Interval. p: p-value. Anti-CCP:
anti-cyclic citrullinated peptide antibodies.
Cox regression model adjusted for sex, age at RA diagnosis and traditional CV risk
factors (hypertension, diabetes mellitus, dyslipidemia, obesity and smoking habit).
doi: 10.1371/journal.pone.0077695.t003
Table 2. Differences in the minor allele frequencies of SMAD3 rs17228212 polymorphism between RA patients with or
without CV events, Ischemic Heart Disease (IHD), Cerebrovascular Accident (CVA) or Heart Failure (HF).
   CV event  IHD  CVA  HF  
  MAF (%) p p* MAF (%) p p* MAF (%) p p* MAF (%) p p*
Anti-CCP Negative absence 27.36   26.97   27.33   26.91   
 presence 25.42 0.54 0.035 27.19 0.96 0.25 21.79 0.29 0.011 29.49 0.62 0.93
Anti-CCP Positive absence 25.74   26.40   26.30   25.92   
 presence 29.45 0.19 0.97 25.00 0.72 0.27 28.05 0.73 0.81 32.00 0.18 0.97
* p: p-value in the logistic regression model adjusted for sex, age at RA diagnosis, follow-up time and traditional CV risk factors (hypertension, diabetes mellitus,
dyslipidemia, obesity, and smoking habit). CV: Cardiovascular; IHD: Ischemic Heart Disease; CVA: Cerebrovascular accident; HF: Heart Failure.
doi: 10.1371/journal.pone.0077695.t002
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atherosclerosis and an independent predictor of myocardial
infarction and stroke both in general population [21], as well as
CV events in RA patients [14].
Previous studies have shown that cIMT correlates well with
pathologically and clinically defined atherosclerosis, and it is
regulated by genetic factors with a heritability ranging from
30% to 60% [22,23]. Subclinical atherosclerosis has been
observed in patients with RA, even in those without classic CV
risk factors [14]. In this regard, several validated noninvasive
imaging techniques are currently available to determine
subclinical atherosclerosis in RA and to study the relation of
surrogate markers with the development of atherosclerosis in
patients with RA [24]. Among them, carotid US has become an
affordable efficient technique to measure the presence of
subclinical atherosclerosis by the assessment of cIMT.
Interestingly, abnormally high values of cIMT (greater than 0.90
mm) have been found to predict the development of CV events
in patients with RA after 5 years of follow-up [14].
Similarities between atherosclerosis and RA, as both are
chronic inflammatory diseases that exhibit similar
pathophysiological mechanisms [25,26], made conceivable the
search for a potential association of SMAD3 rs17228212 gene
variant with CV disease in RA. Our results in Spanish RA
population show for the first time a potential protective effect of
C allele of the SMAD3 rs17228212 polymorphism against risk
of developing CVA in anti-CCP negative patients. The putative
protective effect of the SMAD3 polymorphism in anti-CCP
negative patients seems to be strengthened as there is lower
overall risk of CV events in anti-CCP negative patients.
Additionally, a correlation between presence of C allele of
rs17228212 SMAD3 gene variant in patients who were
negative for anti-CCP antibodies and lower cIMT values were
found after adjustment for demographic and classic CV risk
factors.
Anti-CCP antibodies are highly specific markers of RA and
are detected in 58–82% of patients. In RA patients, these
autoantibodies are associated with greater inflammatory
activity, poorer radiologic outcome, higher frequency of extra-
articular manifestations, and poorer outcomes in early arthritis
[27]. Although the clinical presentation at disease initiation is
Table 4. Association between SMAD3 rs17228212 alleles
and carotid intima-media thickness according to anti-CCP
status in RA patients.
 Anti-CCP negative patients Anti-CCP positive patients
rs1728212
alleles
cIMT mm, mean ±
SD p p*
cIMT mm, mean ±
SD p p*
T 0.71 ± 0.15(n=262)   
0.74 ± 0.17
(n=302)   
C 0.69 ± 0.16 (n=90) 0.28 0.0094 0.75 ± 0.20(n=106) 0.80 0.33
cIMT: carotid intima-media thickness. SD: Standard deviation.
*. p: p-value in the ANCOVA model adjusted for sex, age and duration of the
disease at the time of the ultrasonography study and traditional CV risk factors
(hypertension, diabetes mellitus, dyslipidemia, obesity and smoking habit).
doi: 10.1371/journal.pone.0077695.t004
very similar between patients with anti-CCP-positive and anti-
CCP-negative RA, disease course, possibly disease
pathogenesis [28], and genetic susceptibility [29,30] are
different. Association of RA with the shared epitope is different
in the two serotype subsets [29]; lately it seems that non-HLA
SNPs associated with RA susceptibility are only partially
shared between anti-CCP-positive and anti-CCP-negative RA
patients [28], confirming the hypothesis that anti-CCP-positive
and anti-CCP-negative RA are two genetically different
diseases [31]. Although heritability estimates remain similar in
both serological strata, the contribution of the HLA-DRB1
shared epitope alleles differs markedly, explaining 18% and
2.4% of RA heritability in anti-CCP-positive and anti-CCP-
negative patients, respectively [32]. Previous studies have
shown that anti-CCP antibodies are independently associated
with the development of IHD, and the risk of IHD is irrespective
of the titers of anti-CCP antibodies [27]. This association may
be attributed to chronic inflammation that stimulates the
production of anti-CCP antibodies. Patients with RA treated
with disease-modifying anti-rheumatic drugs have a lower
annual incidence of acute myocardial infarction because
controlling inflammation reduces vascular damage. Our results
would be in agreement with previous findings as they show a
decreased risk of CV complications in the anti-CCP negative
RA patients, which have less radiologic severity and better
clinical outcome (in our study erosions and extra-articular
manifestations were present in 63.01% and 38.48%,
respectively, of anti-CCP positive patients; in anti-CCP
negative patients 38.00% of them have erosions and 27.57%
extra-articular manifestations). It is possible that the lack of
correlation between anti-CCP positive and risk of CV events
could be due to the more aggressive treatment to control the
disease in these anti-CCP positive patients.
Intriguingly, the association observed among anti-CCP
negative RA patients in the present study is in the opposite
direction of that reported by Samani et al [6]. In that study, the
C allele of rs17228212 was found to confer increased risk of
CAD (OR [95%CI]=1.19 [1.09-1.30]), while the present study
reports a protective effect of the C allele against CVA in anti-
CCP negative RA patients (HR [95%CI]= 0.36 [0.14-0.96]).
Because of that, more research is necessary to address that
disparity, as both entities share a common physiological base,
and in both the general population and in patients with RA
cIMT has shown to predict the development of CV events [14].
However, treatments in use in patients suffering those
conditions are different. Therefore, a thorough treatment of this
difference is warranted.
In summary, our results revealed that SMAD3 rs17228212
gene variant is associated with lower risk of CVA and less
severe subclinical atherosclerosis in RA patients negative for
anti-CCP antibodies. These findings may have importance to
establish predictive models of CV disease in RA patients
according to anti-CCP status.
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